This dynamic panel unites gene therapy developers, biotech innovators, and manufacturing leaders to explore challenges in gene therapy production. Panelists will discuss bottlenecks, scalability, and regulatory hurdles while balancing innovation and cost-efficiency. The goal is to identify key risks and unmet needs to shape a high-yield, high-quality, and safe production model, essential for expanding access to life-changing therapies worldwide.
May 6, 16:00-16:45, room MCH Lounge
| Name | Position | Institution |
|---|---|---|
| Eduardo Ayuso | CTO | SIEGFRIED DINAMIQS |
| Name | Position | Institution |
|---|---|---|
| Igor Fisch | CEO | NewBiologix |
| Markus Rüegg | CEO | SEAL Therapeutics |
| Harald Petry | CEO | Avrion Therapeutics |
| Doris Wrobe | Modality Head GT - Portfolio Management CGT | Novartis |
NewBiologix is a biotech company developing Swiss-engineered solutions for gene and cell therapy production. With deep expertise in cell line engineering, it tackles gene therapy manufacturing challenges through advanced cell lines and technologies. By enabling partners to produce safer, more reliable gene therapies faster and at scale, NewBiologix is shaping the future of patient health.
